John Crown

39.6k total citations · 5 hit papers
416 papers, 20.1k citations indexed

About

John Crown is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, John Crown has authored 416 papers receiving a total of 20.1k indexed citations (citations by other indexed papers that have themselves been cited), including 336 papers in Oncology, 132 papers in Pulmonary and Respiratory Medicine and 124 papers in Cancer Research. Recurrent topics in John Crown's work include HER2/EGFR in Cancer Research (157 papers), Cancer Treatment and Pharmacology (125 papers) and Breast Cancer Treatment Studies (84 papers). John Crown is often cited by papers focused on HER2/EGFR in Cancer Research (157 papers), Cancer Treatment and Pharmacology (125 papers) and Breast Cancer Treatment Studies (84 papers). John Crown collaborates with scholars based in Ireland, United States and Germany. John Crown's co-authors include Michael J. Duffy, Norma O’Donovan, Naoise C. Synnott, Martin Clynes, Lorraine O’Driscoll, Michael P. O’Leary, Tadeusz Pieńkowski, Dennis J. Slamon, Patricia M. McGowan and Arlene Chan and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

John Crown

408 papers receiving 19.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

2006 2.5k citations Charles E. Geyer, Stephen Chan et al. profile →
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 1.4k citations John Crown, Tamás Pintér et al. profile →
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

2013 1.2k citations Sherene Loi, Nicolas Sirtaine et al. Journal of Clinical Oncology profile →
Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes

2012 377 citations John Crown, Lorraine O’Driscoll et al. profile →
MYC as a target for cancer treatment

2021 296 citations Michael J. Duffy, Minhong Tang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Crown Ireland	71	13.0k	7.4k	6.0k	4.8k	2.4k	416	20.1k
Masakazu Toi Japan	68	10.8k 0.8×	8.0k 1.1×	6.9k 1.2×	6.1k 1.3×	2.2k 1.0×	666	21.5k
Francisco J. Esteva United States	68	11.6k 0.9×	7.0k 0.9×	4.6k 0.8×	3.2k 0.7×	4.9k 2.1×	280	18.0k
Naoto T. Ueno United States	72	11.0k 0.8×	5.6k 0.7×	6.5k 1.1×	3.7k 0.8×	2.0k 0.9×	547	20.4k
Andreas Schneeweiß Germany	61	13.3k 1.0×	4.6k 0.6×	8.3k 1.4×	4.4k 0.9×	2.3k 1.0×	608	19.1k
Brian Leyland‐Jones United States	53	11.6k 0.9×	5.7k 0.8×	4.6k 0.8×	3.3k 0.7×	4.1k 1.8×	218	18.4k
Patricia LoRusso United States	69	11.2k 0.9×	10.9k 1.5×	2.8k 0.5×	4.4k 0.9×	2.2k 0.9×	569	21.9k
Nicola Normanno Italy	63	10.5k 0.8×	8.4k 1.1×	4.5k 0.8×	5.6k 1.2×	1.9k 0.8×	362	18.5k
Karen A. Gelmon Canada	73	15.9k 1.2×	5.6k 0.8×	7.0k 1.2×	6.6k 1.4×	2.3k 1.0×	393	23.8k
Mario Campone France	66	15.3k 1.2×	7.6k 1.0×	7.1k 1.2×	9.0k 1.9×	3.2k 1.4×	538	23.9k
Aditya Bardia United States	58	10.9k 0.8×	4.0k 0.5×	5.0k 0.8×	5.4k 1.1×	1.8k 0.8×	481	16.1k

Countries citing papers authored by John Crown

Since Specialization

Citations

This map shows the geographic impact of John Crown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Crown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Crown more than expected).

Fields of papers citing papers by John Crown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Crown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Crown. The network helps show where John Crown may publish in the future.

Co-authorship network of co-authors of John Crown

This figure shows the co-authorship network connecting the top 25 collaborators of John Crown. A scholar is included among the top collaborators of John Crown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Crown. John Crown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Crown, John, et al.. (2025). Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. International Journal of Molecular Sciences. 26(2). 460–460.

Tang, Minhong, et al.. (2025). Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630. Investigational New Drugs. 43(1). 167–179. 1 indexed citations

Conlon, Neil T., Sandra Roche, Laura Breen, et al.. (2024). Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo. Translational Oncology. 49. 102073–102073. 2 indexed citations

Miceli, Rosalba, Hanna Eriksson, Giuseppe Lo Russo, et al.. (2024). Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncologica. 63. 213–219. 3 indexed citations

Hurvitz, Sara A., Nicholas P. McAndrew, Aditya Bardia, et al.. (2021). A careful reassessment of anthracycline use in curable breast cancer. npj Breast Cancer. 7(1). 134–134. 33 indexed citations

Walsh, Naomi, Charlotte Andrieu, Peter O’Donovan, et al.. (2020). Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer. British Journal of Cancer. 123(8). 1219–1222. 4 indexed citations

Fehrenbacher, Louis, Reena S. Cecchini, Charles E. Geyer, et al.. (2019). NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology. 38(5). 444–453. 279 indexed citations

Duffy, Michael J., Enda McDermott, & John Crown. (2018). Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. Tumor Biology. 40(5). 3726239216–3726239216. 52 indexed citations

Press, Michael F., José A. Seoane, Christina Curtis, et al.. (2018). Assessment ofERBB2/HER2Status inHER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncology. 5(3). 366–366. 25 indexed citations

10.

Crown, John, Megan Kennedy, Patricia Tresca, et al.. (2013). Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Annals of Oncology. 24(8). 2005–2011. 12 indexed citations

11.

Loi, Sherene, Nicolas Sirtaine, Fanny Piette, et al.. (2013). Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology. 31(7). 860–867. 1213 indexed citations breakdown →

12.

Browne, Brigid C., Alex J. Eustace, Susan Kennedy, et al.. (2012). Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Research and Treatment. 136(3). 717–727. 32 indexed citations

13.

Mulrane, Laoighse, Stephen F. Madden, Donal J. Brennan, et al.. (2012). miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro. Clinical Cancer Research. 18(24). 6702–6713. 71 indexed citations

14.

O’Brien, Neil A., Brigid C. Browne, Lucy Chow, et al.. (2010). Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib. Molecular Cancer Therapeutics. 9(6). 1489–1502. 249 indexed citations

15.

Browne, Brigid C., John Crown, Natarajan Venkatesan, et al.. (2010). Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Annals of Oncology. 22(1). 68–73. 84 indexed citations

16.

Walsh, Naomi, Annemarie Larkin, Susan Kennedy, et al.. (2009). Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urology. 9(1). 6–6. 73 indexed citations

17.

O’Driscoll, Lorraine, Naomi Walsh, A. Larkin, et al.. (2007). MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.. PubMed. 27(4B). 2115–20. 52 indexed citations

18.

Crown, John, et al.. (2005). Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology. 65(2). 331–332. 36 indexed citations

19.

Pegram, M., Tadeusz Pieńkowski, Donald W. Northfelt, et al.. (2004). Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. JNCI Journal of the National Cancer Institute. 96(10). 759–769. 202 indexed citations

20.

Leo, Angelo Di, Stephen Chan, Marianne Paesmans, et al.. (2004). HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel. Breast Cancer Research and Treatment. 86(3). 197–206. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact